Actymthera
Berkeley, US · Founded 2017 · 1 known investors
Actym Therapeutics engineers bacteria as a delivery system for therapeutics targeting cancer and fibrotic disease. Its approach uses engineered S. Typhimurium to systemically administer and locally produce multiple therapeutic payloads at the disease site to reduce systemic toxicity.
Founders & leadership
Actymthera was founded in 2017 by Christopher D Thanos.
CD
Christopher D ThanosFounder
KD
Kanad DasNamed on SEC filing
AK
Amit KumarNamed on SEC filing
JH
James HuangNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$25.3M disclosed across 2 rounds · 2020–2023
▶$11.2MraisedJul 2023 · 5 investors · BiotechnologyRule 506(b)
▶$11.2MraisedJul 2023 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher D ThanosExecutive Officer, Director
- Benjamin ChenDirector
- Ron MazumderDirector
- Julie CherringtonDirector
- Kanad DasDirector
- Offering amount
- $27.5M
- Amount sold
- $11.2M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.1MraisedApr 2020 · 28 investors · BiotechnologyRule 506(b)
▶$14.1MraisedApr 2020 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kanad DasDirector
- Amit KumarDirector, Promoter
- James HuangDirector
- Christopher D ThanosExecutive Officer, Director, Promoter
- Offering amount
- $41.2M
- Amount sold
- $14.1M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Actuate Therapeutics10 shared keywordsClinical-stage therapeutics company focusing on high-impact cancers and inflammatory diseases.
Kite Pharma9 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Agenus8 shared keywords
Context Therapeutics8 shared keywordsContext Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors. Its pipeline targets antigens such as Claudin 6, mesothelin, and Nectin-4 to direct the immune system against difficult-to-treat cancers.
Solu7 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Ifmthera7 shared keywordsIFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer. The company operates through independently financed R&D subsidiaries, each advancing programs aimed at key control nodes of innate immunity such as NLRP3 and cGAS/STING.
Companies competing with Actymthera for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Actymthera do?
- Actym Therapeutics engineers bacteria as a delivery system for therapeutics targeting cancer and fibrotic disease. Its approach uses engineered S. Typhimurium to systemically administer and locally produce multiple therapeutic payloads at the disease site to reduce systemic toxicity.
- Who founded Actymthera?
- Actymthera was founded by Christopher D Thanos in 2017.
- Who are Actymthera's investors?
- Actymthera's investors include Illumina Ventures.
- How much funding has Actymthera raised?
- Actymthera has disclosed $25.3M raised across 2 rounds.
- Where is Actymthera headquartered?
- Actymthera is headquartered in Berkeley, US.